Table 6.

Summary of the most commonly reported adverse events within the Amgen-supported Phase 2 and 3 studies

AEs occurring > 30% of subjects, n (%)a	N = 79
Infection and infestations	38 (48.1)
Gastrointestinal disorders	32 (40.5)
Metabolism and nutritional disorders	30 (38.0)
AEs occurring in ≥ 10% of subjects, n (%)
Hypocalcemia	18 (22.8)
Vomiting	13 (16.5)
Nausea	12 (15.2)
Hypertension	9 (11.4)
Pyrexia	8 (10.1)
Muscle spasms	8 (10.1)
Serious AEs reported for > 2 subjects, n (%)
Hypertension	5 (6.3)
Device-related infection	3 (3.8)
Peritonitis	3 (3.8)

^aDescribed by organ system class. AE, adverse event